Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Vellera Therapeutics Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The docket spans 2 examiners and 2 art units, while LOCKARD, JON MCCLELLAND handles 2 of the pending matters.
The distribution places a meaningful portion of the active work with one examiner, making that examiner’s positions particularly relevant to coordinated claim and amendment planning. The remaining action is assigned through the other examination path, so counsel should preserve application-specific analysis rather than assume uniform treatment.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| No statute on record | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOCKARD, JON MCCLELLAND | 2 | 74.4% | +27.4% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17929874 | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION | BRISTOL, LYNN ANNE | 43d overdue |
| 18695464 | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF | LOCKARD, JON MCCLELLAND | 39d |
| 18695502 | METHOD FOR TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS | LOCKARD, JON MCCLELLAND | 40d |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18695464 | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF | LOCKARD, JON MCCLELLAND | 1647 | Other | Non-Final OA | 39d | Pending | Mar 26, 2024 |
| 18695502 | METHOD FOR TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS | LOCKARD, JON MCCLELLAND | 1647 | Other | Non-Final OA | 40d | Pending | Mar 26, 2024 |
| 17929874 | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION | BRISTOL, LYNN ANNE | 1643 | §112 | Final Rejection | 43d overdue | Pending | Sep 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVellera Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jon Mcclelland Lockard has the most, with 2 of Vellera Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
